Teva Pharmaceutical Industries (TEVA) Enterprise Value (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Enterprise Value across 18 years of filings, most recently posting -$3.7 billion for Q1 2026.

• Quarterly Enterprise Value fell 121.12% year-over-year to -$3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.7 billion (down 121.12% YoY) and the FY2025 annual result came in at -$3.6 billion, down 20.0% from the prior year.
• Enterprise Value retreated to -$3.7 billion in Q1 2026, from -$3.6 billion in the prior quarter.
• Over five years, Enterprise Value peaked at -$1.3 billion in Q1 2022 and troughed at -$3.7 billion in Q1 2026.
• A 5-year average of -$2.3 billion and a median of -$2.1 billion in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2025 — Enterprise Value jumped 38.0% — and 2026, when it plunged 121.12%.
• Tracing TEVA's Enterprise Value over 5 years: stood at -$2.0 billion in 2022, then plunged by 60.74% to -$3.2 billion in 2023, then grew by 8.25% to -$3.0 billion in 2024, then declined by 20.0% to -$3.6 billion in 2025, then dropped by 5.21% to -$3.7 billion in 2026.
• Business Quant data shows TEVA's Enterprise Value at -$3.7 billion in Q1 2026, -$3.6 billion in Q4 2025, and -$2.2 billion in Q3 2025.